Stockreport

Augustine Therapeutics Raises EUR 17 Million in a Series A First Closing to Advance Lead Candidate Into Clinical Development in Neurological Diseases

Vigil Neuroscience, Inc.  (VIGL) 
PDF Proceeds will advance lead candidate AGT100216, a peripherally restricted and selective HDAC6 inhibitor, into a first-in-human clinical Phase 1/2 studyGerhard Koenig app [Read more]